EXACT-HF

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 背景：氧化应激可能导致心力衰竭患者的心室和血管重构，以及疾病的进展。黄嘌呤氧化酶(XO)是心力衰竭时氧化应激的潜在来源，可能是治疗的重要靶点。别嘌醇是一种XO抑制剂，可降低血清尿酸水平，可能对治疗收缩性心力衰竭(HF)患者有用。 假设：在因左心室收缩功能障碍和血尿酸水平升高而出现症状性心力衰竭的患者中，与安慰剂治疗相比，使用别嘌醇治疗24周将改善临床结果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Background: Oxidative stress may contribute to ventricular and vascular remodeling, and disease progression in patients with heart failure. Xanthine oxidase (XO) is a potential source of oxidative stress in heart failure, and may be an important target for therapy. Allopurinol is an XO inhibitor, which reduces serum uric acid levels, and may be useful in the treatment of patients with systolic heart failure (HF). Hypothesis: In patients with symptomatic heart failure due to left ventricular systolic dysfunction and elevated serum uric acid levels, treatment with allopurinol for 24 weeks will improve clinical outcomes compared to treatment with placebo.